

Telomir wins FDA IND clearance for Telomir-Zn in TNBC, enabling a Phase 1/2 study targeting epigenetic cancer pathways.
You can purchase shares of Telomir Pharmaceuticals (NASDAQ:TELO) through any online brokerage.
Other companies in Telomir Pharmaceuticals’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Telomir Pharmaceuticals has a consensus price target of $4.00.
The stock price for Telomir Pharmaceuticals (NASDAQ: TELO) is $1 last updated October 28, 2026 at 5:45 PM EDT.
There are no upcoming dividends for Telomir Pharmaceuticals.
Telomir Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Telomir Pharmaceuticals.
Telomir Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone....